Delisting risk
NewcelX (NCEL)
Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.
$3.48
At close+0.19 (+5.78%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions4 holders · as of Jun 30, 2026 | ≥ 2.65% | 11.9K ADS | |
| Insiders3 holders · as of Apr 29, 2026 | 24.29% | 109.3K ADS | |
| Otherremainder | ≤ 73.06% | 328.8K ADS |
450.0K ADS (1 ADS = 12 ordinary shares) as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2023 annual report; nothing newer is on file here.
Institutional filings for NLSPW (1,200% of the company) are not on file here, so the institutional figure is a floor.
Institutions13F, as of Jun 30, 2026
4 holders · 11.9K shares · 2 new positions · 3 increased · 0 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| HRT Financial LP | 11.2K | 2.49% | +11.2Knew | Aug 14, 2026 |
| Jones Financial Companies LLLP | 700 | 0.16% | +700new | Aug 14, 2026 |
| Caitong International Asset Management Co., Ltd | 9 | 0.00% | +8 | Aug 5, 2026 |
| Corecap Advisors, LLC | 3 | 0.00% | 0 | Jul 6, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| League Jinn Sarlincl. Julien Ruggieri | 25.30% | 13D | May 4, 2026 ↗ | |
| Michel Revel | 20.20% | 13D | Nov 14, 2025 ↗ | |
| Ronald Hafner | 13.20% | 13D | Jun 24, 2025 ↗ | |
| Clover Wolf Capital - Limited Partnership | 7.50% | 13G | Nov 7, 2025 ↗ | |
| Ronen Twito | 6.00% | 13D | Nov 13, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 27, 2026 | Michel Reveldirector, 10 percent owner, officer: CSO and Director | Purchase · 2 lots | 130,908 | $2.91 | 1,033,893 |
| Apr 27, 2026 | Olivier Samueldirector | Purchase · 2 lots | 196,363 | $2.91 | 196,363 |
CongressHouse and Senate disclosures
Not reported.